Support 100 years of independent journalism.

  1. Science & Tech
  2. Coronavirus
24 April 2020updated 06 Oct 2020 9:45am

Antiviral drug remdesivir fails first randomised clinical trial, according to WHO document

By Samuel Horti

Remdesivir, the antiviral drug that many hoped could treat Covid-19, has failed its first randomised clinical trial, according to draft documents accidentally published by the World Health Organization (WHO).

The drug had shown promise in early testing, but a Chinese trial showed that it did not improve patients’ condition or reduce the level of coronavirus in their bloodstreams.

According to the WHO document, scientists gave the drug to 158 people, and gave the remaining 79 a placebo. After a month, 13.9 per cent of patients taking the drug had died compared to 12.8 per cent of the placebo group. The trial was stopped early because of side-effects from the drug.

The company behind the drug, Gilead Sciences, said the document had mischaracterised the study. Trading of its shares was temporarily halted after investors dumped stock.

Sign up for The New Statesman’s newsletters Tick the boxes of the newsletters you would like to receive. Quick and essential guide to domestic and global politics from the New Statesman's politics team. The New Statesman’s global affairs newsletter, every Monday and Friday. The best of the New Statesman, delivered to your inbox every weekday morning. The New Statesman’s weekly environment email on the politics, business and culture of the climate and nature crises - in your inbox every Thursday. A handy, three-minute glance at the week ahead in companies, markets, regulation and investment, landing in your inbox every Monday morning. Our weekly culture newsletter – from books and art to pop culture and memes – sent every Friday. A weekly round-up of some of the best articles featured in the most recent issue of the New Statesman, sent each Saturday. A newsletter showcasing the finest writing from the ideas section and the NS archive, covering political ideas, philosophy, criticism and intellectual history - sent every Wednesday. Sign up to receive information regarding NS events, subscription offers & product updates.

Content from our partners
How do we secure the hybrid office?
How materials innovation can help achieve net zero and level-up the UK
Fantastic mental well-being strategies and where to find them